Dapagliflozin (type 2 diabetes mellitus) - Addendum to Commission A19-53

Report documents

1. Addendum

   Dapagliflozin (type 2 diabetes mellitus) - Addendum to Commission A19-53

   published on

   19.12.2019

   Document type

   PDF document, 129 kB, EN, not accessible

   Download file : Addendum (PDF document, 129 kB, EN, not accessible)

Dossier assessment

Additional information

Project details

Project no.

A19-92

Commission

Commission awarded on 12.12.2019 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Drug Assessment

Topic

Digestion, metabolism and hormones

Note

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Connected Projects

1. Dossier assessment

   Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

   Project no.

   A19-53

   Last updated

   01.10.2019

   Status: Commission completed